JPWO2020131918A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020131918A5 JPWO2020131918A5 JP2021534641A JP2021534641A JPWO2020131918A5 JP WO2020131918 A5 JPWO2020131918 A5 JP WO2020131918A5 JP 2021534641 A JP2021534641 A JP 2021534641A JP 2021534641 A JP2021534641 A JP 2021534641A JP WO2020131918 A5 JPWO2020131918 A5 JP WO2020131918A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- disorder
- compound
- compound according
- status epilepticus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 150000003839 salts Chemical group 0.000 claims description 16
- 208000005809 status epilepticus Diseases 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 206010001497 Agitation Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010039897 Sedation Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000016571 aggressive behavior Effects 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000024732 dysthymic disease Diseases 0.000 claims description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 230000036280 sedation Effects 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 206010002091 Anaesthesia Diseases 0.000 claims description 3
- 230000037005 anaesthesia Effects 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000009575 Angelman syndrome Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000036640 Asperger disease Diseases 0.000 claims description 2
- 201000006062 Asperger syndrome Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 206010004716 Binge eating Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 101710085469 CD2 homolog Chemical group 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Chemical group 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 102100036364 Cadherin-2 Human genes 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000017164 Chronobiology disease Diseases 0.000 claims description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 2
- 206010010071 Coma Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 101000714537 Homo sapiens Cadherin-2 Chemical group 0.000 claims description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000027520 Somatoform disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
- 206010065604 Suicidal behaviour Diseases 0.000 claims description 2
- 206010042458 Suicidal ideation Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 208000009443 Vascular Malformations Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 208000024823 antisocial personality disease Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 230000006399 behavior Effects 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 208000014679 binge eating disease Diseases 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 208000025307 bipolar depression Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 230000010363 phase shift Effects 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 208000022610 schizoaffective disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000012672 seasonal affective disease Diseases 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 206010040030 Sensory loss Diseases 0.000 claims 1
- 229940126027 positive allosteric modulator Drugs 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780703P | 2018-12-17 | 2018-12-17 | |
| US62/780,703 | 2018-12-17 | ||
| PCT/US2019/066923 WO2020131918A1 (en) | 2018-12-17 | 2019-12-17 | Organic compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513933A JP2022513933A (ja) | 2022-02-09 |
| JP2022513933A5 JP2022513933A5 (https=) | 2022-12-23 |
| JPWO2020131918A5 true JPWO2020131918A5 (https=) | 2022-12-23 |
| JP7645797B2 JP7645797B2 (ja) | 2025-03-14 |
Family
ID=71100855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534641A Active JP7645797B2 (ja) | 2018-12-17 | 2019-12-17 | 有機化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12325726B2 (https=) |
| EP (1) | EP3897656A4 (https=) |
| JP (1) | JP7645797B2 (https=) |
| KR (1) | KR102931436B1 (https=) |
| CN (1) | CN113226326B (https=) |
| AU (1) | AU2019406803B2 (https=) |
| BR (1) | BR112021011765A2 (https=) |
| CA (1) | CA3121636A1 (https=) |
| IL (1) | IL283960B2 (https=) |
| MX (1) | MX2021007142A (https=) |
| WO (1) | WO2020131918A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| AU2019406803B2 (en) | 2018-12-17 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| JP2023539125A (ja) * | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2023159094A2 (en) * | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| KR100338287B1 (ko) | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| CN1087725C (zh) * | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| UA73736C2 (en) * | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| RS51304B (sr) * | 2005-06-09 | 2010-12-31 | Euro-Celtique S.A. | Farmaceutske kompozicije neuroaktivnog steroida i njihova upotreba |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| US10577390B2 (en) * | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| CN105985396A (zh) * | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| EP4155314A1 (en) * | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| AU2019406803B2 (en) | 2018-12-17 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2023539125A (ja) | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
-
2019
- 2019-12-17 AU AU2019406803A patent/AU2019406803B2/en active Active
- 2019-12-17 US US17/415,667 patent/US12325726B2/en active Active
- 2019-12-17 IL IL283960A patent/IL283960B2/en unknown
- 2019-12-17 CA CA3121636A patent/CA3121636A1/en active Pending
- 2019-12-17 MX MX2021007142A patent/MX2021007142A/es unknown
- 2019-12-17 BR BR112021011765-2A patent/BR112021011765A2/pt unknown
- 2019-12-17 KR KR1020217022377A patent/KR102931436B1/ko active Active
- 2019-12-17 EP EP19899589.6A patent/EP3897656A4/en active Pending
- 2019-12-17 CN CN201980083634.9A patent/CN113226326B/zh active Active
- 2019-12-17 JP JP2021534641A patent/JP7645797B2/ja active Active
- 2019-12-17 WO PCT/US2019/066923 patent/WO2020131918A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2636324A1 (en) | Cycloalkylamines as monoamine reuptake inhibitors | |
| JP2009531277A5 (https=) | ||
| JP2018104454A5 (https=) | ||
| US5552418A (en) | Trisubstituted Naphthylalkylamides | |
| JP2021519267A5 (https=) | ||
| CN110300753B (zh) | 帽依赖性核酸内切酶抑制剂 | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| TW202430504A (zh) | Ｋ他命的前藥及其組成物及用途 | |
| AU2003208538B2 (en) | Amino acids with affinity for the alpha-2-delta-protein | |
| JP2009527462A5 (https=) | ||
| EP4457222A2 (en) | Nitric oxide releasing prodrugs of mda and mdma | |
| EP3908570A1 (en) | Ketamine pamoate and use thereof | |
| JPWO2020131918A5 (https=) | ||
| JP2014518552A5 (https=) | ||
| JPWO2022040545A5 (https=) | ||
| RU2011107443A (ru) | Индаценовые соединения, фармацевтическая композиция и лекарственное средство на их основе, способ их получения и способ лечения или профилактики состояний, связанных с нарушением функционирования систем, регулируемых мелатонином, с их помощью | |
| RU2006142896A (ru) | Замещенные енаминоны, их производные и их применение | |
| JP2007536262A5 (https=) | ||
| RU2021119458A (ru) | Органические соединения | |
| CN1984878B (zh) | 用于治疗神经变性疾病的1-苯基烷羧酸的衍生物 | |
| EP1176138B1 (en) | Active derivatives of valproic acid for the treatment of neurological and psychotic disorders and a method for their preparation | |
| JP2012509860A5 (https=) | ||
| WO2006027454A1 (fr) | Nouveaux derives du 3,5-seco-4-nor-cholestane et leurs utilisations | |
| RU2289571C2 (ru) | Замещенные производные 5-амино-1-пентен-3-ола, способ их получения и лекарственное средство | |
| HUE024560T2 (hu) | Pantenil-dokozahexanoát, valamint ennek alkalmazása szív-érrendszeri betegségek kezelésére és megelõzésére |